trending Market Intelligence /marketintelligence/en/news-insights/trending/3sxqG3uJTfj5e0MsQPsWug2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cancer drug developer Black Diamond plans to raise $100M via Nasdaq IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Cancer drug developer Black Diamond plans to raise $100M via Nasdaq IPO

Cancer drug developer Black Diamond Therapeutics Inc. seeks to raise about $100 million in gross proceeds with an IPO of its common stock on the Nasdaq Global Market.

Black Diamond is a precision oncology medicine company focusing on the discovery and development of small molecule, tumor-agnostic therapies. It is targeting undrugged mutations in patients with genetically-defined cancers.

The company has applied to list its shares on the exchange under the ticker symbol BDTX.

Black Diamond — led by president and CEO David Epstein — plans to use a majority of the net proceeds from the offering to fund clinical studies, drug discovery and drug development.

This includes the initiation of the phase 1/2 study of its experimental drug, BDTX-189, aimed to treat certain genetic mutations. The study is expected to start in the first half of the year. The company has also submitted an investigational new drug application with the U.S. Food and Drug Administration for the medicine.

Part of the proceeds will also be used for hiring additional personnel, for capital expenditures and other miscellaneous costs.

The Stony Brook, N.Y.-based biotechnology company, previously known as Aset Therapeutics, develops and markets precision medicine for cancer.

Currently, Versant Venture Capital has a 42.09% stake and New Enterprise Associates has an 11.16% stake in the company.

J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Co. LLC are serving as joint book-running managers of the offering and as representatives of the underwriters.